BMRN

BioMarin PharmaceuticalC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$72.00

+35.0% vs current

Most likely

Base case

45%

Probability

Target price

$58.00

+8.8% vs current

B-

Bear case

25%

Probability

Target price

$44.00

-17.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-06

AI commentary

Primary-source tone is constructive on revenue growth, pipeline timing, and the Amicus portfolio addition, but the immediate stock reaction was weak: the packet shows a May 5, 2026 anchor price of $53.24 versus a checked pre-print level of $55.46 one day before the May 4 earnings release, implying roughly a 4% drop as investors focused on EPS dilution, margin pressure, and execution timing. Headline buzz is high because earnings, the Amicus close, and multiple Q2 catalysts all landed together, but the evidence still supports a monitoring-style neutral stance rather than a decisive thesis upgrade.

RankAlpha Sentiment Codex - 2026-05-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventBMN 401 Phase 3 topline data in ENPP1 deficiencyHigh impact

Management said BMN 401 Phase 3 topline data are expected in Q2 2026, with 2H26 regulatory submissions possible if supportive and a potential first-in-disease launch in 2027, making this one of the clearest binary pipeline catalysts in the current setup [#8-K-2026-05-04].

2026-06-30eventVOXZOGO hypochondroplasia Phase 3 readout and regulatory pathHigh impact

BioMarin expects Phase 3 topline data for VOXZOGO in hypochondroplasia in Q2 2026 and said regulatory submissions are anticipated in 2H26 if the data are supportive; the same release also noted the achondroplasia full-approval sNDA was submitted in April with expected acceptance by Q3 2026 [#8-K-2026-05-04].

2026-08-04catalystAmicus integration must convert a raised revenue guide into clean 2H26 executionHigh impact

BioMarin raised 2026 total revenue guidance to $3.825B-$3.925B after adding GALAFOLD and POMBILITI + OPFOLDA, but also guided to slight 2026 non-GAAP EPS dilution and said more than 55% of revenue plus roughly two-thirds of EPS should land in 2H26, leaving the stock dependent on cleaner integration and margin delivery over the next two quarters [#8-K-2026-05-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-06 • Updated nightlySource: Internal modelMethodology